

PHARMACY PRE-AUTHORIZATION CRITERIA

DRUG (S)	Auvi-Q (epinephrine injection device) Symjepi (epinephrine injection device)
POLICY #	12103
INDICATIONS	Auvi-Q and Symjepi contain epinephrine, a non-selective alpha and beta-adrenergic receptor agonist, indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis.
CRITERIA	<p>Connecticare considers Auvi-Q or Symjepi to be medically necessary when all the following criteria are met:</p> <ul style="list-style-type: none">• Patient has had an allergic reaction that has the potential to lead to an emergency, i.e., anaphylactic shock <p>AND</p> <ul style="list-style-type: none">• Patient has a documented contraindication, intolerance or failure of prior use of ALL of the following:<ul style="list-style-type: none">○ EpiPen or EpiPen Jr○ Adrenaclick○ Epinephrine auto injector <p>AND</p> <ul style="list-style-type: none">• Patient has a documented physical or mental health disability requiring an audible and visual assisted device to ensure appropriate administration of injection
LIMITATIONS	The quantity is limited to a maximum of 2 devices per fill.
REFERENCES	<ol style="list-style-type: none">1. Product Information: AUVI-Q^(R) intramuscular injection, subcutaneous injection, epinephrine intramuscular injection, subcutaneous injection. Kaleo Inc (per FDA), Richmond, VA, 2017.2. Product Information: SYMJEPI^(TM) intramuscular injection, subcutaneous injection, epinephrine intramuscular injection, subcutaneous injection. Adamis Pharmaceuticals Corporation (per FDA), San Diego, CA, 2018.
P&T REVIEW HISTORY	2/17, 5/18, 5/19
REVISION RECORD	5/18